Selegiline in the management of apathy following traumatic brain injury

Brain Injury

Volumn 19, Issue 2, 2005, Pages 149-154

  Newburn, Gil ^a   Newburn, Deborah ^a  

^a Rotorua Rehabilitation Clinic   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; METHYLPHENIDATE; SELEGILINE;

ADULT; AGGRESSION; APATHY; ARTICLE; BRAIN INJURY; CASE REPORT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; MOOD DISORDER; PSYCHOLOGIC TEST; RESTLESSNESS; SYMPTOMATOLOGY; XEROSTOMIA;

EID: 13844314242     PISSN: 02699052     EISSN: None     Source Type: Journal    
DOI: 10.1080/02699050410001719989     Document Type: Article

References (32)

1. Teasdale G, Mendelow D. Pathophysiology of head injuries. In: Brooks N, editor. Closed Head Injury. Psychological, Social and Family Consequences. Oxford: Oxford University Press; 1984. pp 5-36.
2. Thornhill S, Teasdale GM, Murray GD, et al. Disability in young people and adults one year after head injury: Prospective cohort study. British Medical Journal 2000;320:1631-5.
3. Marin RS. Differential diagnosis and classification of apathy. American Journal of Psychiatry 1990;147:22-30.
4. Marin RS. Apathy: A neuropsychiatric syndrome. Journal of Neuropsychiatry & Clinical Neuroscience 1991;3:243-54.
5. Marin RS, Firinciogullari S, Biedrzycki RC. The source of convergence between measures of apathy and depression. Journal of Affective Diseases 1993;28:117-24.
6. Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. Journal of Nervous Mental Diseases 1994;182:235-9.
7. Stuss DT, van Reekum R, Murphy KJ. Diferentiation of states and causes of apathy. In: Borod J, editor. Neuropsychology of Emotion. New York: Oxford University Press; 2000, pp 340-63.
8. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Research 1991;38:143-62.
9. Kant R, Duffy JD, Pivovamil A. Prevalence of apathy following head injury. Brain Injury, 1998;12:87-92.
10. Mega MS, Cummings JL. Frontal cortical-subcortical circuits and neuropsychiatric disorder. Journal of Neuropsychiatry & Clinical Neuroscience 1994;6:358-70.
11. Marin RS, Fogel BS, Hawkins J, et al. Apathy: A treatable syndrome. Journal of Neuropsychiatry & Clinical Neuroscience 1995;7:23-30.
12. Kraus MF. Neuropsychiatric sequelae of stroke and traumatic brain injury: The role of psychostimulants. International Journal of Psychiatry Medicine 1995;25:39-51.
13. Watanabe MD, Martin EM, Deleon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. Journal of Neuropsychiatry & Clinical Neuroscience 1995;7:502-4.
14. Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. Journal of Neuropsychiatry & Clinical Neuroscience 1997;9:231-9.
15. Glenn MB. Methylphenidate for cognitive and behavioural dysfunction after traumatic brain injury. Journal of Head Trauma Rehabilitation 1998;13:87-90.
16. Plutchik L, Snyder S, Drooker M, et al. Methylphenidate in post liver transplant patients. Psychosomatics 1998; 39:118-23.
17. Nickels JI, Schneider WN, Dombovy ML, et al. Clinical use of amantadine in brain injury rehabilitation. Brain Injury 1994;8:709-18.
18. van Reekum R, Bayley M, Garner S, et al. N of 1 study: Amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Injury 1995;9:49-53.
19. Zafonte RD, Watanabe T, Mann NR. Amantadine: A potential treatment for the minimally conscious state. Brain Injury 1998;12:617-21.
20. Shiller AD, Burke DT, Kim HJ, et al. Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years duration. Brain Injury 1999;13:715-21.
21. Kraus MF, Maki P. The combined use of amantadine and 1-dopa/carbidopa in the treatment of chronic brain injury. Brain Injury 1997; 11:455-60.
22. Karli DC, Burke DT, Kim HJ, et al. Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury. Brain Injury 1999;13:63-8.
23. Whyte J, Vaccaro M, Grieb-Neff P, et al. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. Journal of Head Trauma Rehabilitation 2002;17:284-99.
24. Meythaler JM, Brunner RC, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized trial. Journal of Head Trauma Rehabilitation 2002; 17:300-13.
25. McDowell S, Whyte J, D'Esposito M. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 1998;121:1155-64.
26. Gualtieri CT. Psychostimulants, dopamine agonists and amantadine. In: Brain Injury and Mental Retardation. Philadelphia: Lippincott Williams & Wilkins; 2002. pp 301-22.
27. Schker J, Behar D. Selegiline for the delivery of small doses of amphetamine. Journal of Neuropsychiatry & Clinical Neuroscience 1997;9:301-2.
28. Zhu J, Hamm RJ, Reeves TM, et al. Post injury administration of L-deprenyl improves cognitive function and enhances neuroplasticity after traumatic brain injury. Experimental Neurology 2000;166:136-52.
29. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington DC: American Psychiatric Association; 2000.
30. Varney NR, Martzke JS, Roberts RJ. Major depression in patients with closed head injury. Neuropsychology 1987; 1:7-9.
31. Jorge RE, Robinson RG, Arndt SV, et al. Depression and traumatic brain injury: A longitudinal study. Journal of Affective Disorders 1993;27:233-43.
32. Kreutzer JS, Seel RT, Gourley E. The prevalence and symptom rates of depression after traumatic brain injury: A comprehensive examination. Brain Injury 2001;15:563-76.